For immediate release |
17 October 2014 |
ANGLE plc
("ANGLE" or "the Company")
KEY OPINION LEADERS REPORT ON PARSORTIX SYSTEM
ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce positive reports from four of its key opinion leaders on the operation of ANGLE's Parsortix system to analyse circulating tumour cells (CTCs).
The 2nd International Symposium on Advances in Circulating Tumor Cells (ACTC) was held from 8 to 11 October 2014 in Crete. At the event, there were oral presentations on the Parsortix system from Cancer Research UK Manchester (CRUK) and the Medical University of Vienna (Vienna), and poster presentations from The University Medical Center Hamburg-Eppendorf (UKE) and Barts Cancer Institute (Barts). Barts is a new key opinion leader and further details are provided in a separate announcement today.
All four key opinion leaders reported key strengths of the Parsortix system compared with other systems. These included:
· CRUK: The Parsortix system does not rely on antibody-based capture and is thus applicable to all types of CTCs including mesenchymal CTCs. The Parsortix system offers an exceptionally high level of purity of harvested CTCs enabling molecular analysis
· Vienna: The Parsortix system can handle large volumes of patient blood, up to 20ml, and continues to capture CTCs efficiently. CTCs harvested from the Parsortix system can be analysed using qPCR (an established form of molecular analysis) and the Parsortix system efficiently reduces the level of contaminating white blood cell background to below the limit of detection of qPCR
· UKE: The Parsortix system is an effective device for the enrichment of epithelial and/or mesenchymal-like CTCs. The system overcomes hurdles of label-dependent techniques since it is not based on antibody affinity capture. Using the Parsortix system, tumour cells as well as tumour cell clusters are easily accessible and ready for molecular analysis
· Barts: the Parsortix system worked well with prostate cancer patients. The Parsortix system captured a high purity of CTCs and was 30 times purer than a leading antibody-based system. The Parsortix CTC harvest was well suited for downstream molecular analysis and was demonstrated with fluorescence in-situ hybridisation analysis (an established form of molecular analysis).
The conference was well attended with over 300 delegates from all over Europe, the United States and many other countries. The presentations from the four key opinion leaders generated a great deal of interest in the Parsortix system from other leading cancer research centres.
ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"The strategy of marketing the Parsortix system through the use of key opinion leaders is progressing well and we were delighted with the response to the system at the ACTC conference. The universally positive message from four world class key opinion leaders is a powerful statement of the competitive advantages of the Parsortix system in the personalised cancer care market."
For further information:
ANGLE plc |
01483 685830 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
Cenkos Securities Stephen Keys, Dr Christopher Golden (Nominated adviser) Andy Roberts, Christian Hobart (Sales) |
020 7397 8900 |
Buchanan Mark Court, Fiona Henson, Sophie Cowles |
020 7466 5000 |
|
|
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
